ARQTArcutis Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Arcutis Biotherapeutics, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARQTEsta | $3.0B#15 | 108.4x#3 | 13.6x#5 | 8.0x#3 | 91.3%#6 | 88.5%#4 | -3.3%#5 | -7.3%#4 | -4.1%#2 | — | — | — |
| MDGL | $12.4B#4 | — | 23.7x#8 | 13.0x#4 | 432.1%#2 | 38.1%#5 | -31.3%#6 | -55.0%#7 | -52.5%#4 | — | 23.5%#10 | — |
| TGTX | $8.4B#11 | 19.9x#2 | 13.8x#6 | 13.6x#5 | 87.3%#7 | 1811.1%#1 | 20.0%#3 | 74.0%#1 | 14.2%#1 | — | 83.8%#6 | — |
| INSM | $26.3B#1 | — | 34.7x#11 | 43.4x#8 | 66.7%#8 | -39.7%#10 | -205.6%#8 | -168.6%#10 | -163.0%#6 | 3#1 | — | — |
| SRRK | $6.8B#12 | — | 26.9x#10 | — | — | -53.7%#12 | — | -148.9%#9 | -2854.7%#7 | — | 69.2%#7 | — |
| APGE | $10.2B#7 | — | — | — | — | -40.5%#11 | — | — | — | — | 256.9%#2 | — |
| PTGX | $9.5B#10 | 142.4x#4 | 11.3x#4 | 206.3x#10 | -89.4%#11 | -147.3%#14 | -343.6%#9 | -15.5%#5 | -36.7%#3 | — | 149.5%#5 | — |
| SMMT | $11.5B#6 | — | 18.3x#7 | — | — | -387.8%#15 | — | -171.4%#11 | — | — | -39.4%#11 | — |
| UTHR | $22.0B#2 | 18.4x#1 | 3.4x#1 | 6.9x#2 | 10.6%#9 | 11.7%#6 | 46.9%#2 | 20.9%#2 | — | — | — | — |
| PRAX | $9.8B#9 | — | 7.3x#2 | — | -100.0%#12 | -65.6%#13 | — | -22.6%#6 | — | — | 685.7%#1 | — |
| ARWR | $11.7B#5 | — | 25.2x#9 | 14.1x#6 | 23258.2%#1 | 99.7%#3 | 11.9%#4 | -0.4%#3 | — | — | 222.9%#3 | — |
| COGT | $6.0B#13 | — | 11.3x#3 | 761.0x#11 | -65.0%#10 | -28.6%#7 | -4235.3%#11 | -61.8%#8 | -84.3%#5 | — | 187.7%#4 | — |
| BBIO | $15.0B#3 | — | — | 29.9x#7 | 126.3%#4 | -34.9%#9 | -104.2%#7 | — | — | — | — | 0.0%#1 |
| PTCT | $5.8B#14 | — | — | 3.4x#1 | 114.5%#5 | 288.0%#2 | 50.1%#1 | — | — | — | 33.5%#9 | — |
| CYTK | $10.0B#8 | — | — | 113.4x#9 | 376.6%#3 | -33.2%#8 | -695.4%#10 | — | — | — | 45.0%#8 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice